The coronavirus vaccine developed jointly by BioNTech and Pfizer is “still effective” against the Omicron variant of the virus after three doses, the German company said in a statement on Wednesday.
According to the statement, an Omicron-specific version of the jab, currently in development by BioNTech, would be available “by March.”
They claim three doses of the jab is sufficient to inoculate an individual against the highly mutated and rapidly spreading Omicron variant of the virus.
Nigeria recently announced its first cases of the variant, which was first discovered in South Africa last month.
The discovery led to sweeping travel ban on numerous African countries, including Nigeria.